NLS Pharmaceutics: Nasdaq OK; merger to close Oct 30, 2025

NLS Pharmaceutics Ltd. (NLSP) furnished a Form 6-K announcing it issued a press release titled “NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025.” The press release is included as Exhibit 99.1.

Rhea-AI Filing Summary

NLS Pharmaceutics Ltd. (NLSP) furnished a Form 6-K announcing it issued a press release titled “NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025.” The press release is included as Exhibit 99.1.

This update indicates Nasdaq approval has been received and the parties expect to close the merger on October 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NLSP announce in this Form 6-K?

NLSP furnished a press release stating that Nasdaq approval was received and the merger with Kadimastem is expected to close on October 30, 2025.

When is the NLS–Kadimastem merger expected to close?

The merger is expected to close on October 30, 2025.

What approval did NLS Pharmaceutics receive?

The companies announced receipt of Nasdaq approval related to the merger.

Where can I find more details about the announcement?

Details are in the press release furnished as Exhibit 99.1 to the Form 6-K.

What is the form type and company ticker?

This is a Form 6-K furnished by NLS Pharmaceutics Ltd. (NLSP).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/23/2025 - 06:04 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025 (Report No. 3)

Commission File Number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On October 23, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025.” A copy of this press release is furnished herewith as Exhibit 99.1.

1

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: October 23, 2025	By:	/s/ Alexander C. Zwyer
		Name:	Alexander C. Zwyer
		Title:	Chief Executive Officer

3